Board to consider September 2026 quarterly and half-year results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
No consolidated or standalone financial figures are disclosed in this meeting notice. The board will meet on 10 November 2026 to approve unaudited results for the quarter and half year ended 30 September 2026, along with the limited review report for the quarter. No revenue, profit, cash flow or other financial details are provided.
No immediate impact can be assessed; the stock may react when the results and limited review report are published.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.